Deaths in Brazil raise concerns about India’s dengue vaccine, DengiAll
The suspension of a dengue vaccine in Brazil due to safety concerns has prompted calls for caution regarding India's upcoming DengiAll vaccine. Both vaccines share similar tetravalent, live-attenuated virus technology, raising questions about potential immune-mediated risks.
Why it matters
Understanding the biological risks of cross-reactive antibodies is critical for public health safety as India prepares to roll out a major new immunization program.
The recent death of two people in Brazil during its dengue vaccination campaign, leading to the shot’s suspension on June 8, is a crucial wake-up call for India. This is because the dengue vaccine in Brazil, Butantan-DV, is pretty similar, if not identical, to India’s soon-to-be-launched dengue vaccine, DengiAll.
The report focuses on scientific and public health concerns regarding vaccine safety without taking a stance on the vaccine's ultimate viability.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in